Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
amsterdamumc.nlLive pipeline data from ClinicalTrials.gov, refreshed daily.
Total trials
520
Active
166
Phase 3
36
Total enrollment
259,133
Pipeline matrix
Showing 40 of 55 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Botulinum toxin type A | — | — | — | — | — | 1 | |
| Dupilumab | — | — | — | — | — | 1 | |
| HOP bundle | — | — | — | — | — | 1 | |
| Reduced noradrenaline use | — | — | — | — | — | 1 | |
| Rifaximin 550 milligram Oral Tablet [XIFAXAN] | — | — | — | — | — | 1 | |
| Lactulose 667 milligram/milliliter Oral Solution | — | — | — | — | — | 1 | |
| Hyperbaric oxygen | — | — | — | — | — | 1 | |
| Vedolizumab | — | — | — | — | — | 1 | |
| Carboplatin | — | — | — | 6 | |||
| Paclitaxel | — | — | — | 6 | |||
| Trastuzumab | — | — | — | — | — | 1 | |
| Pertuzumab | — | — | — | — | — | 1 | |
| Tranexamic Acid 500Mg | — | — | — | — | — | 1 | |
| Ziltivekimab | — | — | — | — | — | 1 | |
| Chemotherapy | — | — | — | — | — | 1 | |
| Targeted Systemic Therapy | — | — | — | — | — | 1 | |
| Immunotherapy | — | — | — | — | — | 1 | |
| Immune Globulin Intravenous | — | — | — | — | — | 1 | |
| Infliximab subcutaneous | — | — | — | — | — | 1 | |
| Immunosuppressive Agents | — | — | — | — | — | 1 | |
| Fluvoxamine | — | — | — | — | — | 1 | |
| Fentanyl Citrate | — | — | — | — | — | 1 | |
| Esketamine | — | — | — | — | — | 1 | |
| Capecitabine | — | — | — | — | — | 4 | |
| Oxaliplatin | — | — | — | — | — | 2 | |
| carboplatin + paclitaxel | — | — | — | — | — | 1 | |
| Nadroparin Injectable Product | — | — | — | — | — | 1 | |
| nivolumab 480mg | — | — | — | — | — | 1 | |
| nivolumab 3mg/kg, ipilimumab 1mg/kg | — | — | — | — | — | 1 | |
| nivolumab 1mg/kg, ipilimumab 3mg/kg | — | — | — | — | — | 1 | |
| freezedried autologous encapsulated fecal microbiota transplantation | — | — | — | — | — | 1 | |
| Flecainide | — | — | — | — | — | 1 | |
| Flecainide + beta-blocker | — | — | — | — | — | 1 | |
| Ataluren + Pembrolizumab | — | — | — | — | — | 1 | |
| Retifanlimab | — | — | — | — | — | 1 | |
| Hyperbaric Oxygen Therapy | — | — | — | — | — | 1 | |
| Omeprazole 40 MG | — | — | — | — | — | 1 | |
| Icosapent ethyl | — | — | — | — | — | 1 | |
| Terbinafine | — | — | — | — | — | 1 | |
| Tenofovir | — | — | — | — | — | 1 |
15 more active programs hidden
Next readouts
- 2022-10-10
- 2023-06-01
- 2024-07
- 2024-07-31
- 2024-08
- 2024-12-31
- 2025-01-01
- 2025-04-01
- 2025-05-01
- 2025-05-01
Top conditions
- Prostate Cancer10
- Esophageal Cancer8
- Sickle Cell Disease8
- Anesthesia7
- Surgery7
- Colorectal Cancer7
- Coronary Artery Disease6
- Obesity6
Frequently asked questions about Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
- How many clinical trials does Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) have on ClinicalTrials.gov?
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) is listed as the lead sponsor on 520 clinical trials in ClinicalTrials.gov, 166 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)'s trials are in Phase 3?
- 36 of Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)'s trials are in Phase 3, spread across 55 active drug programs.
- What therapeutic areas does Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) focus on?
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)'s most-studied conditions on ClinicalTrials.gov are Prostate Cancer, Esophageal Cancer, Sickle Cell Disease, Anesthesia, Surgery.
- When are Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)'s next clinical trial readouts?
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) has 10 upcoming primary-completion readouts tracked here; the soonest is “Blood-borne Assessment of Stromal Activation in Esophageal Adenocarcinoma to Guide Tocilizumab Therapy”, expected around 2022-10-10.